The MOPEAD project: Advancing patient engagement for the detection of "hidden" undiagnosed cases of Alzheimer's disease in the community.


Journal

Alzheimer's & dementia : the journal of the Alzheimer's Association
ISSN: 1552-5279
Titre abrégé: Alzheimers Dement
Pays: United States
ID NLM: 101231978

Informations de publication

Date de publication:
06 2019
Historique:
received: 09 11 2018
revised: 30 01 2019
accepted: 25 02 2019
pubmed: 12 5 2019
medline: 23 6 2020
entrez: 12 5 2019
Statut: ppublish

Résumé

In most, if not all health systems, dementia is underdiagnosed, and when diagnosis occurs, it is typically at a relatively late stage in the disease process despite mounting evidence showing that a timely diagnosis would result in numerous benefits for patients, families, and society. Moving toward earlier diagnoses in Alzheimer's disease (AD) requires a conscientious and collective effort to implement a global strategy addressing the multiple causes hindering patient engagement at different levels of society. This article describes the design of the Models of Patient Engagement for Alzheimer's Disease project, an ongoing EU-funded public-private multinational initiative that will compare four innovative patient engagement strategies across five European countries regarding their ability to identify individuals with prodromal AD and mild AD dementia, which are "hidden" in their communities and traditionally not found in the typical memory clinic setting. The strategies include an online AD citizen science platform, an open house initiative at the memory clinics, and patient engagement at primary care and diabetologist clinics.

Identifiants

pubmed: 31076376
pii: S1552-5260(19)30072-X
doi: 10.1016/j.jalz.2019.02.003
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

828-839

Informations de copyright

Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.

Auteurs

Octavio Rodríguez-Gómez (O)

Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades - Universitat Internacional de Catalunya, Barcelona, Spain; Networking Research Center on Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, Barcelona, Spain. Electronic address: orodriguez@fundacioace.org.

Adrián Rodrigo (A)

GMV SECURE E SOLUTIONS, Valencia, Spain.

Fátima Iradier (F)

Eli Lilly and Company (Lilly España), Alcobendas, Spain.

Miguel A Santos-Santos (MA)

Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades - Universitat Internacional de Catalunya, Barcelona, Spain.

Hans Hundemer (H)

Eli Lilly and Company (Lilly Deutschland GmbH), Bad Homburg, Germany.

Andreea Ciudin (A)

Vall d'Hebron Research Institute (VHIR) and CIBERDEM (ISCIII), Barcelona, Spain.

Lena Sannemann (L)

Department of Psychiatry, University of Cologne, Cologne, Germany.

Marissa Zwan (M)

Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands.

Bridget Glaysher (B)

Modus Research and Innovation Limited, Dundee, Scotland.

Anders Wimo (A)

Division of Neurogeriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Huddinge, Sweden.

Jaka Bonn (J)

Center for Cognitive Impairments, Department of Neurology, University Medical Center Ljubljana, Ljubljana, Slovenia.

Gunilla Johansson (G)

Division of Neurogeriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Huddinge, Sweden.

Isabel Rodriguez (I)

Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades - Universitat Internacional de Catalunya, Barcelona, Spain.

Montse Alegret (M)

Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades - Universitat Internacional de Catalunya, Barcelona, Spain; Networking Research Center on Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, Barcelona, Spain.

Dianne Gove (D)

Alzheimer Europe, Luxembourg.

Susana Pinó (S)

Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades - Universitat Internacional de Catalunya, Barcelona, Spain.

Paloma Trigueros (P)

GMV SECURE E SOLUTIONS, Valencia, Spain.

Miia Kivipelto (M)

Division of Clinical Geriatrics, Centre for Alzheimer Research, Department of Neurobiology, Care Sciences, and Society, Karolinska Institutet, Stockholm, Sweden; Institute of Clinical Medicine/Neurology, University of Eastern Finland, Kuopio, Finland.

Brandy Mathews (B)

Eli Lilly and Company, Indianapolis, IN, USA.

Antonio Ciudad (A)

Eli Lilly and Company (Lilly España), Alcobendas, Spain.

Daniel Ferreira (D)

Division of Clinical Geriatrics, Centre for Alzheimer Research, Department of Neurobiology, Care Sciences, and Society, Karolinska Institutet, Stockholm, Sweden.

Christophe Bintener (C)

Alzheimer Europe, Luxembourg.

Miren Gurruchaga (M)

Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades - Universitat Internacional de Catalunya, Barcelona, Spain.

Eric Westman (E)

Division of Clinical Geriatrics, Centre for Alzheimer Research, Department of Neurobiology, Care Sciences, and Society, Karolinska Institutet, Stockholm, Sweden; Department of Neuroimaging, Centre for Neuroimaging Sciences, Institute of Psychiatry, Psychology, and Neuroscience, King's College London, London, UK.

Mark Belger (M)

Eli Lilly and Company (Lilly UK), Surrey, UK.

Sergi Valero (S)

Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades - Universitat Internacional de Catalunya, Barcelona, Spain; Networking Research Center on Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, Barcelona, Spain.

Peggy Maguire (P)

European Institute of Womenś Health, Dublin, Ireland.

David Krivec (D)

Združenje Spominčica, Ljubljana, Slovenia.

Milica Kramberger (M)

Center for Cognitive Impairments, Department of Neurology, University Medical Center Ljubljana, Ljubljana, Slovenia.

Rafael Simó (R)

Vall d'Hebron Research Institute (VHIR) and CIBERDEM (ISCIII), Barcelona, Spain.

Inmaculada Pérez Garro (IP)

GMV SECURE E SOLUTIONS, Valencia, Spain.

Pieter Jelle Visser (PJ)

Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands; Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University, Maastricht, the Netherlands.

Annette Dumas (A)

ASDM Consulting, Brussels, Belgium.

Jean Georges (J)

Alzheimer Europe, Luxembourg.

Frank Jessen (F)

Department of Psychiatry, University of Cologne, Cologne, Germany; German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.

Bengt Winblad (B)

Division of Neurogeriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Huddinge, Sweden; Karolinska Univ Hospital, Theme Aging, Stockholm, Sweden.

Craig Shering (C)

AstraZeneca, Waltham, MA, USA.

Neil Stewart (N)

Modus Research and Innovation Limited, Dundee, Scotland.

Laura Campo (L)

Eli Lilly and Company, Firenze, Italy.

Mercè Boada (M)

Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades - Universitat Internacional de Catalunya, Barcelona, Spain; Networking Research Center on Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, Barcelona, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH